Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MAGE-A10 A*02:01 TCR-T
- Development stage
- Unknown
- Lead developer
- Adaptimmune Therapeutics
- Modality
- TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
MAGE-A10 A*02:01 TCR-T is an autologous T-cell receptor engineered T-cell (TCR-T) therapy being developed by Anocca AB. The therapy consists of patient-derived T cells that are engineered using proprietary non-viral gene editing technology to express a T-cell receptor specific for the MAGE-A10 peptide presented on the HLA-A*02:01 major histocompatibility complex. MAGE-A10 is a cancer-testis antigen that is highly expressed in several solid tumors, including melanoma, lung cancer, and bladder cancer, but has restricted expression in normal tissues, making it a suitable target for immunotherapy. The mechanism of action involves the recognition and subsequent lysis of tumor cells expressing the MAGE-A10/HLA-A*02:01 complex by the engineered T cells. The product is manufactured at Anocca's in-house cGMP facility and is currently in Phase 1 clinical development.
- Other names
- Anocca MAGE-A10 TCR-TMAGE-A10 HLA-A*02:01 TCR-T cell therapyAnocca-MAGE-A10 (presented on HLA-A*02:01)-TCR-T
02
Targets
HLA-A*02 (Human leukocyte antigen A*02 complexed peptide)
Beyond the preview
Go deeper on MAGE-A10 A*02:01 TCR-T.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MAGE-A10 A*02:01 TCR-T.